Lanx adds to exec team; MiMedx gets CE certificaiton for CollaFix surgical mesh CD;

> Broomfield, CO-based Lanx has added to its executive team in operations, international, clinical & regulatory affairs, marketing, R&D and legal. In addition, Lanx has expanded its corporate facility, and combined its operations into a single 80,000-square-foot facility. Lanx has reported the completion of the Durango stand-alone ALIF System pre-launch evaluation, with 100 successful implantations. Full commercial launch of the system is under way. Release | Release

> MiMedx Group has received CE certification for the its CollaFix surgical mesh CD, which is a Class III product in Europe. MiMedx release

> Starkey Laboratories is changing its parent company name to Starkey Hearing Technologies. The 45-year-old company is making the change based on its overall technology focus, global expansion and a changing marketplace. Starkey release

> Varian Medical Systems ($VAR) has received FDA 510(k) clearance for a new radiotherapy treatment planning tool designed to work with its Eclipse software to reduce the amount of time needed for planning advanced treatments. Varian release

> BioView has sold its first circulating tumor cells screening device to Taiwan Academia Sinica. BioView's system distinguishes healthy cells from tumor cells and can diagnose tumors from very small samples. Story

> Venture capital firm Interwest Partners has appointed Dr. Reza Zadno as a venture partner. Zadno will source new investments, work with existing portfolio companies and help to refine the firm's investment strategy in medical devices. Interwest release

And Finally... After years of predictions that the "$1,000 genome" was coming soon, a company is saying it has achieved that milestone and taken the technology several steps ahead. Ion Torrent, a division of Life Technologies, has a genome-sequencing machine that is 1,000 times more powerful than existing technology, according to CEO and chairman Jonathan Rothberg. Item

Suggested Articles

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.